Newsroom

  • Category

  • By Date

  • Press Release

    07 April 26

    Aurobindo arm CuraTeQ reports positive Phase 3 results for allergy drug BP11

    Aurobindo Pharma unit CuraTeQ reports positive Phase 3 data for Xolair biosimilar BP11 in chronic spontaneous urticaria, plans EMA and FDA filings by end of Q2 2026

    Read more